公开(公告)号：US20080206843A1

公开(公告)日：2008-08-28

申请号：US11977844

申请日：2007-10-26

Applicant: Vincent Brian Croud ,  John Collinge ,  Graham Jackson

Inventor： Vincent Brian Croud ,  John Collinge ,  Graham Jackson

IPC: C11D7/42

CPC classification number: A61L2/16 ,  A01N37/16 ,  A23L3/3499 ,  A23L3/3508 ,  A23L3/3571 ,  A61L2/186 ,  A61L2202/24 ,  C11D3/386 ,  C11D3/3947 ,  C11D3/48 ,  C11D11/0041 ,  A01N2300/00 ,  A01N25/30 ,  A01N37/46 ,  A01N61/00 ,  A01N63/00 ,  A01N63/02 ,  A01N63/04 ,  A01N65/00

Abstract: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.

Abstract translation: 本发明涉及朊病毒降解，去污或消毒的组合物和方法。 组合物包含氧化剂，一种或多种蛋白酶和表面活性剂如离子表面活性剂/洗涤剂。 该方法包括使朊病毒污染的实体与包含有效量的氧化剂，有效量的至少一种蛋白酶和有效量的表面活性剂的朊病毒降解组合物接触。 组合物的组分可以使用水性组合物依次或同时与朊病毒污染的实体接触。 通常使用至少两种不同的蛋白酶来获得最佳疗效。 优选地，氧化剂包括全乙酰离子或其源。 本发明还涉及包含各种试剂的试剂盒。

公开(公告)号：US06534036B1

公开(公告)日：2003-03-18

申请号：US09431887

申请日：1999-11-02

Applicant: John Collinge ,  Anthony R. Clarke ,  Graham S. Jackson

Inventor： John Collinge ,  Anthony R. Clarke ,  Graham S. Jackson

IPC: A61K4900

CPC classification number: A61K49/0058 ,  A61K38/00 ,  A61K51/1018 ,  C07K14/47 ,  C07K16/2872

Abstract: The present invention relates to a method of making a &bgr;-form of a prion protein which preferably has more &bgr;-sheet than &agr;-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the &bgr;-form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native &agr;-form of a prion protein to a &bgr;-form, and to uses of identified compounds in medicine.

公开(公告)号：US6090550A

公开(公告)日：2000-07-18

申请号：US860050

申请日：1997-08-28

Applicant: John Collinge ,  David Thornley

Inventor： John Collinge ,  David Thornley

IPC: C12N15/09 ,  C12Q1/68 ,  G06F17/30 ,  C12P19/34 ,  G01N33/00

CPC classification number: C12Q1/6869 ,  Y10T436/143333

Abstract: A method of automatically sequencing DNA comprises repeatedly determining the next base in the sequence as a function not only of a physical measurement made at that position, but also as a function of previously-determined near-by bases in the same sequence. Typically, a computer algorithm is used which predicts the value of the expected measurement at a given position based upon a knowledge of the bases in previous and/or subsequent positions. The predicted measurement is then compared with the actual measurement, and the base chosen at that position is the base which minimizes the accumulated error measure for the entire sequence. The preferred algorithm, which may be parallel or sequential, preferably includes physical modelling of the replication effect and of the fluorescence effect.

Abstract translation: PCT No.PCT / GB95 / 03026 Sec。 371日期1997年8月28日 102（e）日期1997年8月28日PCT提交1995年12月22日PCT公布。 公开号WO96 / 20286 日期1996年7月4日DNA自动测序DNA的方法包括重复地确定序列中的下一个碱基，作为不仅在该位置进行的物理测量的功能，而且还作为先前确定的相邻碱基的函数 序列。 通常，使用计算机算法，其基于在先前和/或后续位置中的基础的知识来预测给定位置处的期望测量值。 然后将预测的测量与实际测量值进行比较，并且在该位置处选择的基数是使整个序列的累积误差测量最小化的基础。 可以是平行或顺序的优选算法优选地包括复制效应和荧光效应的物理建模。

公开(公告)号：US10288627B2

公开(公告)日：2019-05-14

申请号：US13824307

申请日：2011-09-13

Applicant: Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

Inventor： Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

IPC: G01N33/68

Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.

公开(公告)号：US20110311510A1

公开(公告)日：2011-12-22

申请号：US13221417

申请日：2011-08-30

Applicant: Vincent Brian CROUD ,  John Collinge ,  Graham Jackson

Inventor： Vincent Brian CROUD ,  John Collinge ,  Graham Jackson

IPC: A01N63/02 ,  A01P1/00 ,  A01N37/44

CPC classification number: A61L2/16 ,  A01N37/16 ,  A23L3/3499 ,  A23L3/3508 ,  A23L3/3571 ,  A61L2/186 ,  A61L2202/24 ,  C11D3/386 ,  C11D3/3947 ,  C11D3/48 ,  C11D11/0041 ,  A01N2300/00 ,  A01N25/30 ,  A01N37/46 ,  A01N61/00 ,  A01N63/00 ,  A01N63/02 ,  A01N63/04 ,  A01N65/00

Abstract: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.

Abstract translation: 本发明涉及朊病毒降解，去污或消毒的组合物和方法。 组合物包含氧化剂，一种或多种蛋白酶和表面活性剂如离子表面活性剂/洗涤剂。 该方法包括使朊病毒污染的实体与包含有效量的氧化剂，有效量的至少一种蛋白酶和有效量的表面活性剂的朊病毒降解组合物接触。 组合物的组分可以使用水性组合物依次或同时与朊病毒污染的实体接触。 通常使用至少两种不同的蛋白酶来获得最佳疗效。 优选地，氧化剂包括全乙酰离子或其源。 本发明还涉及包含各种试剂的试剂盒。

公开(公告)号：US07550144B2

公开(公告)日：2009-06-23

申请号：US10535938

申请日：2003-11-28

Applicant: John Collinge ,  Simon Hawke

Inventor： John Collinge ,  Simon Hawke

IPC: A61K39/395 ,  A61K39/04 ,  A61K38/00

CPC classification number: C07K16/18 ,  A61K2039/505

Abstract: The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.

Abstract translation: 本发明涉及使用诸如能够与PrP反应的抗体的药物在预防受试者中的朊病毒复制，治疗或预防朊病毒感染中用于治疗或预防与朊病毒感染有关的神经病理学 制备用于治疗或预防朊病毒疾病的药物。 此外，本发明涉及治疗朊病毒疾病的方法，抑制朊病毒复制的方法和用于此类方法的抗体。

公开(公告)号：US20060280745A1

公开(公告)日：2006-12-14

申请号：US10535938

申请日：2003-11-28

Applicant: John Collinge ,  Simon Hawke

Inventor： John Collinge ,  Simon Hawke

IPC: A61K39/395 ,  C07K16/40

CPC classification number: C07K16/18 ,  A61K2039/505

Abstract: The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.

公开(公告)号：US20060217282A1

公开(公告)日：2006-09-28

申请号：US10532265

申请日：2003-10-29

Applicant: Graham Jackson ,  John Collinge ,  Anthony Clarke

Inventor： Graham Jackson ,  John Collinge ,  Anthony Clarke

IPC: C11D3/386

CPC classification number: C11D3/48 ,  A61B90/70 ,  A61L2/07 ,  A61L2/16 ,  A61L2/18 ,  C11D3/386

Abstract: The present invention relates to methods for prion decontamination comprising (i) contacting an entity to be decontaminated with a detergent, (ii) contacting said entity with one or more protease(s), and optionally (iii) autoclaving said entity. The invention further relates to kits comprising detergents and proteases for prion decontamination, and compositions comprising detergents and proteases for prion decontamination.

Abstract translation: 本发明涉及用于朊病毒去污的方法，其包括（i）使待去污染的实体与洗涤剂接触，（ii）使所述实体与一种或多种蛋白酶接触，和任选地（iii）高压灭菌所述实体。 本发明还涉及包含用于朊病毒去污的洗涤剂和蛋白酶的试剂盒，以及包含洗涤剂和蛋白酶用于朊病毒去污的组合物。

公开(公告)号：US20060029547A1

公开(公告)日：2006-02-09

申请号：US11140416

申请日：2005-05-27

Applicant: John Collinge ,  Anthony Clarke ,  Graham Jackson

Inventor： John Collinge ,  Anthony Clarke ,  Graham Jackson

IPC: A61K49/00 ,  C12P21/06 ,  C07K14/47

CPC classification number: A61K49/0058 ,  A61K38/00 ,  A61K51/1018 ,  C07K14/47 ,  C07K16/2872

Abstract: The present invention relates to a method of making a β-form of a prion protein which preferably has more β-sheet than α-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the β-form in medicine, especially for raising to antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native α-form of a prion protein to a β-form, and to uses of identified compounds in medicine.

Abstract translation: 本发明涉及一种制备朊蛋白的β型的方法，其优选比α-螺旋结构具有更多的β-折叠，并且在不存在变性剂和/或非聚集的情况下是可溶的，并表现出对 用蛋白酶K消化。本发明还涉及β-形式在药物中的用途，特别是用于提供可用于治疗和/或诊断朊病毒疾病的抗体。 本发明还涉及筛选能够抑制和/或逆转天然α-形式的朊病毒蛋白转化为β型的化合物的方法，以及在药物中使用鉴定的化合物。